Reuters
"Even though (the data) is impressive for a new molecular entity - it has no direct evidence to support the antiviral activity," said panel member Susanne May, who voted against authorization of the drug. May is a professor of biostatistics with the University of Washington School of Public Health and director of the UW Clinical Trials Center.
Category